Abstract
Cyanobacteria are considered a promising source for new pharmaceutical lead compounds and a large number of chemically diverse and bioactive metabolites have been obtained from cyanobacteria over the last few decades. This review highlights the structural diversity of natural products from freshwater and terrestrial cyanobacteria. The review is divided into three areas: cytotoxic metabolites, protease inhibitors, and antimicrobial metabolites. The first section discusses the potent cytotoxins cryptophycin and tolytoxin. The second section covers protease inhibitors from freshwater and terrestrial cyanobacteria and is divided in five subsections according to structural class: aeruginosins, cyanopeptolins, microviridins, anabaenopeptins, and microginins. Structure activity relationships are discussed within each protease inhibitor class. The third section, antimicrobial metabolites from freshwater and terrestrial cyanobacteria, is divided by chemical class in three subsections: alkaloids, peptides and terpenoids. These examples emphasize the structural diversity and drug development potential of natural products from freshwater and terrestrial cyanobacteria.
Keywords: Cyanobacteria, cytotoxic, protease inhibitor, antibacterial, antifungal, protease inhibitors, chemodiversity, NRPS, PKS, genome sequence
Current Drug Targets
Title: Chemodiversity in Freshwater and Terrestrial Cyanobacteria – A Source for Drug Discovery
Volume: 12 Issue: 11
Author(s): George E. Chlipala, Shunyan Mo and Jimmy Orjala
Affiliation:
Keywords: Cyanobacteria, cytotoxic, protease inhibitor, antibacterial, antifungal, protease inhibitors, chemodiversity, NRPS, PKS, genome sequence
Abstract: Cyanobacteria are considered a promising source for new pharmaceutical lead compounds and a large number of chemically diverse and bioactive metabolites have been obtained from cyanobacteria over the last few decades. This review highlights the structural diversity of natural products from freshwater and terrestrial cyanobacteria. The review is divided into three areas: cytotoxic metabolites, protease inhibitors, and antimicrobial metabolites. The first section discusses the potent cytotoxins cryptophycin and tolytoxin. The second section covers protease inhibitors from freshwater and terrestrial cyanobacteria and is divided in five subsections according to structural class: aeruginosins, cyanopeptolins, microviridins, anabaenopeptins, and microginins. Structure activity relationships are discussed within each protease inhibitor class. The third section, antimicrobial metabolites from freshwater and terrestrial cyanobacteria, is divided by chemical class in three subsections: alkaloids, peptides and terpenoids. These examples emphasize the structural diversity and drug development potential of natural products from freshwater and terrestrial cyanobacteria.
Export Options
About this article
Cite this article as:
E. Chlipala George, Mo Shunyan and Orjala Jimmy, Chemodiversity in Freshwater and Terrestrial Cyanobacteria – A Source for Drug Discovery, Current Drug Targets 2011; 12 (11) . https://dx.doi.org/10.2174/138945011798109455
DOI https://dx.doi.org/10.2174/138945011798109455 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Review of Therapeutic Effects of Curcumin
Current Pharmaceutical Design Rediscovering the Antibiotics of the Hive
Recent Patents on Anti-Infective Drug Discovery Nicotine Vaccines
CNS & Neurological Disorders - Drug Targets Harnessing the Natural Pool of Polyketide and Non-ribosomal Peptide Family: A Route Map towards Novel Drug Development
Current Molecular Pharmacology DNA Methyltransferase-1 Inhibitors as Epigenetic Therapy for Cancer
Current Cancer Drug Targets Editorial [Hot Topic: Drug Targets in Viral Infections (Guest Editor: Jean-Marc Sabatier)]
Infectious Disorders - Drug Targets CCL2-CCR2 Signaling in Disease Pathogenesis
Endocrine, Metabolic & Immune Disorders - Drug Targets In Silico Approach to Finding New Active Compounds from Histone Deacetylase (HDAC) Family
Current Pharmaceutical Design Is the Cytoskeleton an Intracellular Receptor for Adrenomedullin and PAMP?
Current Protein & Peptide Science Inflammation-Mediating Proteases: Structure, Function in (Patho) Physiology and Inhibition
Protein & Peptide Letters Natural Products as Anti-Cancerous Therapeutic Molecules Targeted towards Topoisomerases
Current Protein & Peptide Science Patent Annotations
Recent Patents on DNA & Gene Sequences Angiogenesis Inhibitors and Radiation in Multimodality Cancer Therapy: Preclinical and Clinical Studies
Current Angiogenesis (Discontinued) Hypoxic Tumor Microenvironment and Cancer Cell Differentiation
Current Molecular Medicine The New Patient and Responsible Self-Medication Practices: A Critical Review
Current Drug Safety Use of Insulin and Insulin Analogs and Risk of Cancer — Systematic Review and Meta-Analysis of Observational Studies
Current Drug Safety Synergistic Cytotoxicity Effect of 5-Fluorouracil and SHP2 Inhibitor Demethylincisterol A3 on Cervical Cancer Cell
Anti-Cancer Agents in Medicinal Chemistry Drug Resistance and Apoptosis in Cancer Treatment: Development of New Apoptosis-Inducing Agents Active in Drug Resistant Malignancies
Current Medicinal Chemistry - Anti-Cancer Agents Antitumor Effects of Celastrol and Semi-Synthetic Derivatives
Mini-Reviews in Organic Chemistry Signal Transduction and Heavy Ion Radiation Therapy: Biological Mechanisms, Biological Quality Assurance, and New Multimodality Approach
Current Signal Transduction Therapy